Market Cap 469.60B
Revenue (ttm) 61.16B
Net Income (ttm) 4.23B
EPS (ttm) N/A
PE Ratio 24.33
Forward PE 18.82
Profit Margin 6.91%
Debt to Equity Ratio -12.03
Volume 1,579,156
Avg Vol 6,935,440
Day's Range N/A - N/A
Shares Out 1.77B
Stochastic %K 79%
Beta 0.30
Analysts Strong Sell
Price Target $276.37

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 847 932 7900
Address:
1 North Waukegan Road, North Chicago, United States
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 27 at 6:35 PM
$SLS $MRK $MRNA $ABBV Very Often the all knowing "market" missprices equity ... $ABVX a Perfect Example: had been bumping around $5 and change in the days/weeks before its P3 Results were announced and it had doubled to $10 ... the day the P3 Was Announced T1 Trading Halt - and a +600% Gap UP Open at $60 Per Share. from $10 to $60 in an Instant and it Kept climbing to a high of $148 ... Something very similar is about to happen here. ANY DAY NOW
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 27 at 6:20 PM
$SLS $MRK $MRNA $ABBV • 60th to 78th, 28.72 Days Per Event • its now been 108 Days since the 78th ... • or 54 Days Per Event should the 80th occur today with a PR After Hours. ANY DAY NOW and the whole market will See Gps Phase 3 Results: 36 Month MOS vs < 10 for Control ... 600M Shares will trade this up into the Triple Digits.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 27 at 5:43 PM
$SLS $MRK $MRNA GPS Phase 2 MOS in CR1 was 67.6 Months. SOC / Onureg MOS is 24.7 Months. • GPS MOS 67.6 not reached vs 24.7 it is not that complicated. $ABBV Combined Onureg (Aza) with Venetoclax for First Remission Patients (CR1) - VIALE-M FAILED. $15 will be $150 and climbing.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 27 at 5:41 PM
$SLS $MRK $MRNA $ABBV for the Inch thick mile wide in the back -- when this $15 stock is $150 and you're all, i woulda coulda shoulda --- remember you were TOLD. IDMC UNBLINDED ACTUAL PHASE 3 INTERIM MOS and IR DATA - from the ONGOING Phase 3. AML Players Can Know and Do know - why we are seeing Miraculous Survival in this Imminently due Registrational Phase 3 Trials. MRNA added $40B to its MCAP in a Day ... SLS is about to do something Similar.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 27 at 5:38 PM
$SLS $MRK $MRNA $ABBV Gps Share Price will launch $26/$30 Per Share, on the Now Truly Imminent 80th Event PR, like it has on all prior event announcements*. - this $15 Stock will be a $150 Stock and MORE when the P3 Results come in: GPS will Triple Survival - like it has in most other trials - GPS MOS 34/36 Months, BAT < 10 - will see 600m Shares trade - 50K AML Patients get into remission each year $30B TAM - Gps will set records for patient uptake rates, 3x 4x OS advantage Pristine Safety, easy in home Subq administration, Low Cost High Margin Manufacture - GPS+ IP rights into 2047. • 60th to 78th, 28.72 Days Per Event • its now been 108 Days since the 78th ... • or 54 Days Per Event should the 80th occur today with a PR After Hours.
0 · Reply
BenUnknown
BenUnknown Aug. 27 at 5:09 PM
$IBRX $NGEN May I add that NerveGen is the only current pharmacological treatment option for folks with nerve damage / Spinal cord injury. MIRACLE drug, huge market. Excellent and I mean excellent phase 2 study. FDA in alignment on phase 3 that starts next month. Just moved to the Nasdaq at the start of this year (undiscovered biotech). Fully funded to Q1 2028. Just diluted share holders to achieve that financial health (so the shares are dirt cheap). Anywho, just my opinion, insane amount of green flags and an asymmetrical opportunity for insane returns. Here’s a chart of revenue with just 10% of market penetration for spinal cord injury (no current drug approvals in that field) and $ABBV just failed their phase 2 for spinal cord injuries. Compare our current market cap to those revenues and you’ll get a glimpse of the possible returns. It’s the most insane set up I’ve ever seen. I’ll shut up now, thank you for attending my TED talk🫶🏻🥂
1 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 27 at 4:58 PM
$SLS @rancho77 what do you mean, If this is actually true? What the actual F.? JFC People --- $ABBV recently Conducted 3 Large AZA+VEN Phase 3 Trials - that FAILED Aza+VEN is BAT - Best Available Treatment for the SLS CONTROL ARM - and it FAILED a First Remission Maintenance Trial ....due to SLOW Accrual - MY ASS -- people were dying from the toxicity. WE are SEEING MIRACULOUS SURVIVAL IN THE SLS Second Remission Maintenance Trial ... it ain't BAT... I've been here longer than methusalah - if you are interested in MONEY ... scroll my posts for DD. Lmk if you have any questions. ps all the lying short scumbags are buy signs. pss only a matter of time and this $15 stock is $150 and more... From Dr. T.
0 · Reply
Primeoptionsst
Primeoptionsst Aug. 27 at 4:15 PM
$ABBV $257.5 28 AUG 26 (W) PUT 100 $1.04 ➡️ $2.08 100% GAINER!
0 · Reply
Biotech_Beast
Biotech_Beast Aug. 27 at 4:12 PM
$SYRE In September, SYRE will report 12 week data from ulcerative colitis patients treated with SPY003, an anti IL-23. $ABBV's Skyrizi already has pretty convenient dosing, so it might be hard to differentiate the agent much there. Then there is data in Q4'26 from SPY072 in PsA and axSpA. https://seekingalpha.com/article/4940789-spyre-therapeutics-catalyst-rich-period-but-easiest-money-may-have-been-made
0 · Reply
Snipertradesexpert
Snipertradesexpert Aug. 27 at 3:55 PM
$ABBV $257.5 28 AUG 26 (W) PUT 100 $1.04 ➡️ $2.08 100% GAINER!
0 · Reply
Latest News on ABBV
AbbVie submits Skyrizi application to the EMA

2026-08-27T09:21:03.000Z - 9 hours ago

AbbVie submits Skyrizi application to the EMA


AbbVie price target raised to $300 from $295 at Wells Fargo

2026-08-17T10:55:57.000Z - 10 days ago

AbbVie price target raised to $300 from $295 at Wells Fargo


AbbVie price target raised to $260 from $246 at Evercore ISI

2026-08-10T12:16:02.000Z - 17 days ago

AbbVie price target raised to $260 from $246 at Evercore ISI


AbbVie upgraded to Buy from Hold at Erste Group

2026-08-05T14:36:14.000Z - 22 days ago

AbbVie upgraded to Buy from Hold at Erste Group


AbbVie price target raised to $288 from $261 at Guggenheim

2026-08-04T10:52:04.000Z - 23 days ago

AbbVie price target raised to $288 from $261 at Guggenheim


AbbVie price target raised to $290 from $282 at Canaccord

2026-08-03T11:06:04.000Z - 24 days ago

AbbVie price target raised to $290 from $282 at Canaccord


AbbVie says ‘quite pleased’ with Skyrizi momentum

2026-07-31T14:01:14.000Z - 27 days ago

AbbVie says ‘quite pleased’ with Skyrizi momentum


AbbVie sees Q3 adjusted EPS $3.84-$3.88, consensus $3.84

2026-07-31T13:30:48.000Z - 27 days ago

AbbVie sees Q3 adjusted EPS $3.84-$3.88, consensus $3.84


AbbVie Earnings Call Transcript: Q2 2026

Jul 31, 2026, 9:00 AM EDT - 27 days ago

AbbVie Earnings Call Transcript: Q2 2026


AbbVie Earnings release: Q2 2026

Jul 31, 2026, 9:00 AM EDT - 27 days ago

AbbVie Earnings release: Q2 2026


AbbVie Quarterly report: Q2 2026

Jul 31, 2026, 9:00 AM EDT - 27 days ago

AbbVie Quarterly report: Q2 2026


AbbVie Reports Second-Quarter 2026 Financial Results

Jul 31, 2026, 7:47 AM EDT - 27 days ago

AbbVie Reports Second-Quarter 2026 Financial Results


JUVÉDERM® Day Returns to U.S. on August 19

Jul 30, 2026, 8:00 AM EDT - 4 weeks ago

JUVÉDERM® Day Returns to U.S. on August 19


AbbVie to Host Second-Quarter 2026 Earnings Conference Call

Jun 26, 2026, 8:00 AM EDT - 2 months ago

AbbVie to Host Second-Quarter 2026 Earnings Conference Call


AbbVie's $11 Billion Immunology Bet

Jun 24, 2026, 12:51 PM EDT - 2 months ago

AbbVie's $11 Billion Immunology Bet

APGE


AbbVie to Buy Apogee Therapeutics for $10.9 Billion

Jun 22, 2026, 10:15 AM EDT - 2 months ago

AbbVie to Buy Apogee Therapeutics for $10.9 Billion

APGE


AbbVie Transcript: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 2 months ago

AbbVie Transcript: M&A announcement


AbbVie Slides: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 2 months ago

AbbVie Slides: M&A announcement


AbbVie Press release: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 2 months ago

AbbVie Press release: M&A announcement


AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash

Jun 22, 2026, 7:42 AM EDT - 2 months ago

AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash

APGE


AbbVie strikes $10.9 billion deal for Apogee Therapeutics

Jun 22, 2026, 7:04 AM EDT - 2 months ago

AbbVie strikes $10.9 billion deal for Apogee Therapeutics

APGE


AbbVie Declares Quarterly Dividend

Jun 18, 2026, 4:05 PM EDT - 2 months ago

AbbVie Declares Quarterly Dividend


55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 27 at 6:35 PM
$SLS $MRK $MRNA $ABBV Very Often the all knowing "market" missprices equity ... $ABVX a Perfect Example: had been bumping around $5 and change in the days/weeks before its P3 Results were announced and it had doubled to $10 ... the day the P3 Was Announced T1 Trading Halt - and a +600% Gap UP Open at $60 Per Share. from $10 to $60 in an Instant and it Kept climbing to a high of $148 ... Something very similar is about to happen here. ANY DAY NOW
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 27 at 6:20 PM
$SLS $MRK $MRNA $ABBV • 60th to 78th, 28.72 Days Per Event • its now been 108 Days since the 78th ... • or 54 Days Per Event should the 80th occur today with a PR After Hours. ANY DAY NOW and the whole market will See Gps Phase 3 Results: 36 Month MOS vs < 10 for Control ... 600M Shares will trade this up into the Triple Digits.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 27 at 5:43 PM
$SLS $MRK $MRNA GPS Phase 2 MOS in CR1 was 67.6 Months. SOC / Onureg MOS is 24.7 Months. • GPS MOS 67.6 not reached vs 24.7 it is not that complicated. $ABBV Combined Onureg (Aza) with Venetoclax for First Remission Patients (CR1) - VIALE-M FAILED. $15 will be $150 and climbing.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 27 at 5:41 PM
$SLS $MRK $MRNA $ABBV for the Inch thick mile wide in the back -- when this $15 stock is $150 and you're all, i woulda coulda shoulda --- remember you were TOLD. IDMC UNBLINDED ACTUAL PHASE 3 INTERIM MOS and IR DATA - from the ONGOING Phase 3. AML Players Can Know and Do know - why we are seeing Miraculous Survival in this Imminently due Registrational Phase 3 Trials. MRNA added $40B to its MCAP in a Day ... SLS is about to do something Similar.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 27 at 5:38 PM
$SLS $MRK $MRNA $ABBV Gps Share Price will launch $26/$30 Per Share, on the Now Truly Imminent 80th Event PR, like it has on all prior event announcements*. - this $15 Stock will be a $150 Stock and MORE when the P3 Results come in: GPS will Triple Survival - like it has in most other trials - GPS MOS 34/36 Months, BAT < 10 - will see 600m Shares trade - 50K AML Patients get into remission each year $30B TAM - Gps will set records for patient uptake rates, 3x 4x OS advantage Pristine Safety, easy in home Subq administration, Low Cost High Margin Manufacture - GPS+ IP rights into 2047. • 60th to 78th, 28.72 Days Per Event • its now been 108 Days since the 78th ... • or 54 Days Per Event should the 80th occur today with a PR After Hours.
0 · Reply
BenUnknown
BenUnknown Aug. 27 at 5:09 PM
$IBRX $NGEN May I add that NerveGen is the only current pharmacological treatment option for folks with nerve damage / Spinal cord injury. MIRACLE drug, huge market. Excellent and I mean excellent phase 2 study. FDA in alignment on phase 3 that starts next month. Just moved to the Nasdaq at the start of this year (undiscovered biotech). Fully funded to Q1 2028. Just diluted share holders to achieve that financial health (so the shares are dirt cheap). Anywho, just my opinion, insane amount of green flags and an asymmetrical opportunity for insane returns. Here’s a chart of revenue with just 10% of market penetration for spinal cord injury (no current drug approvals in that field) and $ABBV just failed their phase 2 for spinal cord injuries. Compare our current market cap to those revenues and you’ll get a glimpse of the possible returns. It’s the most insane set up I’ve ever seen. I’ll shut up now, thank you for attending my TED talk🫶🏻🥂
1 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 27 at 4:58 PM
$SLS @rancho77 what do you mean, If this is actually true? What the actual F.? JFC People --- $ABBV recently Conducted 3 Large AZA+VEN Phase 3 Trials - that FAILED Aza+VEN is BAT - Best Available Treatment for the SLS CONTROL ARM - and it FAILED a First Remission Maintenance Trial ....due to SLOW Accrual - MY ASS -- people were dying from the toxicity. WE are SEEING MIRACULOUS SURVIVAL IN THE SLS Second Remission Maintenance Trial ... it ain't BAT... I've been here longer than methusalah - if you are interested in MONEY ... scroll my posts for DD. Lmk if you have any questions. ps all the lying short scumbags are buy signs. pss only a matter of time and this $15 stock is $150 and more... From Dr. T.
0 · Reply
Primeoptionsst
Primeoptionsst Aug. 27 at 4:15 PM
$ABBV $257.5 28 AUG 26 (W) PUT 100 $1.04 ➡️ $2.08 100% GAINER!
0 · Reply
Biotech_Beast
Biotech_Beast Aug. 27 at 4:12 PM
$SYRE In September, SYRE will report 12 week data from ulcerative colitis patients treated with SPY003, an anti IL-23. $ABBV's Skyrizi already has pretty convenient dosing, so it might be hard to differentiate the agent much there. Then there is data in Q4'26 from SPY072 in PsA and axSpA. https://seekingalpha.com/article/4940789-spyre-therapeutics-catalyst-rich-period-but-easiest-money-may-have-been-made
0 · Reply
Snipertradesexpert
Snipertradesexpert Aug. 27 at 3:55 PM
$ABBV $257.5 28 AUG 26 (W) PUT 100 $1.04 ➡️ $2.08 100% GAINER!
0 · Reply
Alphatrades09
Alphatrades09 Aug. 27 at 3:55 PM
$ABBV $2.08 here.🔥 +100% GAINER. 👑🚀
0 · Reply
Alphatrades09
Alphatrades09 Aug. 27 at 3:47 PM
WHO’S WATCHING FOR THE NEXT $ABBV-STYLE SETUP? 👀 The $ABBV puts moved strongly right at market open today. 📉 I’m keeping an eye out for another setup that fits my plan. Stay tuned and manage your risk. 🔥
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 27 at 3:44 PM
$SLS $ABBV conducted 3 large Phase 3 Aza+VEN Trials, that FAILED - Aza+VEN is the Best Available Treatment (BAT) for the SLS PH3 CONTROL ARM. While we are Seeing Miraculous Survival in the SLS PH3 -- 40% of these Frail, CR2 Second Remission Patients who are Ineligible for Transplant, who have a 6-8 month MOS< are Surving Nearly 3 years . .. and $ABBV 's VIALE-M Ph3 for First Remission Patients, Failed BECAUSE THEY COULD NOT ENROLL PATIENTs... YOU WOULD THINK WITH MIRACULOUS SURVIVAL - ABBV WOULD HAVE SEEN RECORD TIME ENROLLMENT -but it failed.... VIALE-M CR1 Transplant Ineligible - Remission Maintenance Trial Failed.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 27 at 3:31 PM
$SLS $MRK $MRNA Why was $ABBV unable to enroll patients on Aza+VEN, the BAT for the SLS P3 Control ARM ? • while we are seeing miraculous extended survival in the SLS p3? $ABBV Claims they Could NOT ENROLL patients on Aza+VEN. Gps has proven Effective in preventing relapse and extending survival IN EVERY PREVIOUS TRIAL -- Including 2 Phase 2 Trials for AML Remission Maintenance. *Phase 3 Trial Results Imminent. Oral Aza -Onureg is the SOC for AML Patients in First Remission - achieved a MOS of 24.7 Months. $ABBV Conducted the VIALE-M PH3 trial Combining Oral Az w Venetoclax - it FAILED. GPS MOS in this Same First Remission Setting Achieved PH2 MOS >67.6 Months. SOC: 24.7 --- GPs: > 67.6 Again Note the Key Gps Specific Immune Response. Onureg Ph3 and GPS P2 Patients were not Eligible for Transplant. 6.7% of the Onureg CR1 Patients Subsequently rec'd transplant. I’ve been here a long time if your interested in Money scroll my posts.
0 · Reply
Alphatrades09
Alphatrades09 Aug. 27 at 2:37 PM
One of my Telegram members and followers just locked in a 🔥 +$116 profit on $ABBV! 💰📈
0 · Reply
Beamen216
Beamen216 Aug. 27 at 2:17 PM
$ABBV I'm thinking 252
0 · Reply
Snipertradesexpert
Snipertradesexpert Aug. 27 at 2:07 PM
$1.85 on $ABBV here! 🩸 77% return! 🔥
0 · Reply
MrCashFlow1
MrCashFlow1 Aug. 27 at 2:06 PM
$ABBV$1.85 ➡️ 77% gain 🩸🔥 Solid move
0 · Reply
DERICKTRADE
DERICKTRADE Aug. 27 at 2:03 PM
$1.85 on $ABBV here! 🩸🔥 +77% RETURN! 🚀💰
0 · Reply
Primeoptionsst
Primeoptionsst Aug. 27 at 2:02 PM
$1.85 on $ABBV here! 77% return! 🔥
0 · Reply
Alphatrades09
Alphatrades09 Aug. 27 at 2:02 PM
$ABBV $1.85 here. +77% move. 🔥
0 · Reply
Primeoptionsst
Primeoptionsst Aug. 27 at 1:54 PM
$ABBV UPDATE 🚨 ABBV is showing some weakness today, currently around $258.68 (-1.61%). Key level: $260 👀 If ABBV can reclaim and hold $260, I’d want to see buyers push it back toward $261$263. If it continues trading below $260, especially if $258 breaks, momentum could remain bearish. ⚠️ Don’t chase the move. I want confirmation before calling the reversal. Bullish above $260 📈 | Bearish below $258 📉 Watching closely. 🔥
0 · Reply